TY - JOUR
T1 - Diagnosis and management of asthma in adults a review
AU - McCracken, Jennifer L.
AU - Veeranki, Sreenivas P.
AU - Ameredes, Bill T.
AU - Calhoun, William J.
N1 - Publisher Copyright:
© 2017 American Medical Association. All rights reserved.
PY - 2017/7/18
Y1 - 2017/7/18
N2 - IMPORTANCE Asthma affects about 7.5%of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. OBSERVATIONS Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-Acting β2-Agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-Acting β2-Agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-Acting β2-Agonists alone is not appropriate. Other controller approaches include long-Acting muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab). CONCLUSIONS AND RELEVANCE Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, use of short-Acting β2-Agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-Acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents.
AB - IMPORTANCE Asthma affects about 7.5%of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. OBSERVATIONS Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-Acting β2-Agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-Acting β2-Agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-Acting β2-Agonists alone is not appropriate. Other controller approaches include long-Acting muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab). CONCLUSIONS AND RELEVANCE Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, use of short-Acting β2-Agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-Acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents.
UR - http://www.scopus.com/inward/record.url?scp=85025802077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025802077&partnerID=8YFLogxK
U2 - 10.1001/jama.2017.8372
DO - 10.1001/jama.2017.8372
M3 - Review article
C2 - 28719697
AN - SCOPUS:85025802077
SN - 0098-7484
VL - 318
SP - 279
EP - 290
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 3
ER -